Emepronium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Emepronium
Accession Number
DB13505
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 282.45
Monoisotopic: 282.221626326
Chemical Formula
C20H28N
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Emepronium.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Emepronium.
AclidiniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Emepronium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Emepronium.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Emepronium.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Emepronium.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Emepronium.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Emepronium.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Emepronium.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
A03CA30 — Emepronium and psycholepticsN05CX05 — Emepronium, combinationsG04BD01 — Emepronium
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Aralkylamines / Tetraalkylammonium salts / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Organic cations
Substituents
Amine / Aralkylamine / Aromatic homomonocyclic compound / Diphenylmethane / Hydrocarbon derivative / Organic cation / Organic nitrogen compound / Organic salt / Organonitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
04QQ8SWA4U
CAS number
27892-33-7
InChI Key
JEJBJBKVPOWOQK-UHFFFAOYSA-N
InChI
InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
IUPAC Name
(4,4-diphenylbutan-2-yl)(ethyl)dimethylazanium
SMILES
CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
31386
RxNav
3816
ChEBI
135169
ChEMBL
CHEMBL2110805
Wikipedia
Emepronium_bromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.8e-06 mg/mLALOGPS
logP0.15ALOGPS
logP0.68ChemAxon
logS-7.7ALOGPS
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.68 m3·mol-1ChemAxon
Polarizability34.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on June 23, 2017 14:43 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates